

***University of California  
System-Wide Technology Transfer Forum  
Cardiovascular Disease***

***Speaker Biographies***

**Ann Bonham, Ph.D.**

Executive Associate Dean for Research and Professor of Medical Pharmacology and Toxicology, UC Davis

Dr. Ann Bonham earned a Ph.D. in pharmacology from the University of Iowa College of Medicine, and completed a post-doctoral fellowship at Northwestern University School of Medicine. She is currently Executive Associate Dean for Research and Professor of Medical Pharmacology and Toxicology, and is a national leader in the field of central neural regulation of cardiovascular and respiratory functions and how gender, environmental pollutants, physiological changes and disease alter this regulation. She has been a member of the UC Davis faculty for the past 18 years. As Executive Associate Dean, Dr. Bonham oversees UC Davis Health System's research programs. These programs focus on high-impact discoveries, bench-bedside research, and interdisciplinary, collaborative research with public, private and industry partners. Dr. Bonham also serves as editor of the *Journal of Physiology*. She has played a major role in UC Davis' expansion of basic biomedical sciences in pharmacogenomics, neurosciences, and membrane and vascular biology. In the past she has served as Chair of the Department of Medical Pharmacology and Toxicology, as Vice Chair of Research for the Department of Internal Medicine, as Associate Chief of Research for the Division of Cardiovascular Medicine, and as Acting Chief of the Division Cardiovascular Medicine. Dr. Bonham has received several awards and distinctions, including being twice awarded the UC Davis Kaiser Award for Excellence in Teaching Science Basic to Medicine. She was also honored with the American Medical Women's Association Gender Equity Award for providing a gender-fair environment for the education and training of women physicians.

**G. Steven Burrill**

Chief Executive Officer

Burrill & Company

G. Steven Burrill is Chief Executive Officer of Burrill & Company, a San Francisco based life sciences merchant bank focused exclusively on companies involved in biotechnology, pharmaceuticals, diagnostics, devices, human healthcare and related medical technologies, nutraceuticals and wellness, agricultural biotechnology, and industrial biotechnology (biomaterials/bioprocesses). Burrill & Company's business revolves around two core activities: Venture Capital (with over \$500 million under management) and Merchant Banking. In 2002, Mr. Burrill was recognized as the biotech investment visionary by the prestigious *Scientific American* magazine (*The Scientific American* 50). He currently serves as Chairman of the Boards of Icoria (NASDAQ: ICOR), Pharmasset, and Pyxis Genomics; and is a member of the Boards of Directors of

Catalyst Biosciences, DepoMed (Amex: DMI), Galapagos Genomics, Targacept, and Third Wave Technologies (NASDAQ: TWTI). Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide.

As an internationally recognized spokesman for the life sciences and high technology industries, Mr. Burrill has authored a variety of articles and books, including his most recent industry report, *Biotech 2005—Life Sciences: A Move Towards Predictability*. Mr. Burrill is a founder of the Foundation for the National Medals of Science and Technology and currently serves on its Board of Directors. He also serves on the Boards of Directors for the Bay Area Science Infrastructure Consortium, BayBio, the California Healthcare Institute, the Exploratorium, the Kellogg Center for Biotechnology, and the University of California, San Francisco (UCSF) Foundation. Mr. Burrill also serves on the Advisory Boards for BioExecutive, BioProcess, Hadasit, and the University of Hawaii Medical School, as well as serving as Chairman of the San Francisco Mayor's Biotechnology Advisory Council (MayBAC). In addition, he is a member of The World Bank's "Out of the Box" group as well as an adjunct professor at the University of California, San Francisco (UCSF).

**Warren S. Grundfest, M.D.**

Professor, School of Engineering and  
School of Surgery, UCLA

Dr. Grundfest is Professor of Biomedical Engineering, Professor of Electrical Engineering, and Professor of Surgery, Division of Surgical Oncology, at the University of California, Los Angeles. Dr. Grundfest received his M.D. from Columbia University, College of Physicians & Surgeons, in 1980. In 1985 Dr. Grundfest became Director of Laser Surgery & Surgical Research at Cedars-Sinai Medical Center, and in 1987 was appointed Assistant Director of its Department of Surgery and Assistant Clinical Professor of Surgery at UCLA.

Dr. Grundfest developed microendoscopy as a tool for the study of acute coronary ischemic syndromes, and pioneered the development of minimally invasive techniques for the treatment of atherosclerotic cardiovascular disease. His many honors and distinctions include being elected Fellow of the American Institute of Medical & Biologic Engineers (AIMBE) for pioneering development and dissemination of minimally invasive surgery, and being elected Fellow of the Society of Photo-Optical Instrumentation Engineers (SPIE) for his contributions to the field of optical engineering in medicine and biology. In 1994 Dr. Grundfest was inducted into NASA's Space Technology Hall of Fame for the application of Excimer lasers to biologic systems. Dr. Grundfest is also a past member of the Surgery and Bioengineering Study Section of the National Institutes of Health Center for Scientific Review; has chaired multiple review panels; and regularly consults for the NIH and the FDA.

**Kirk U. Knowlton, M.D.**

Chief, Division of Cardiology, UC San Diego

Dr. Knowlton is Chief of the division of Cardiology and Professor of Medicine at the University of California, San Diego. He received a B.A. in Chemistry at Brigham Young University and an M.D. from the University of Utah. Dr. Knowlton completed his Residency in the Department of Internal Medicine at Duke University and a Fellowship in Cardiology at the University of California, San Diego. Dr. Knowlton has received numerous honors and awards, including the Haskel Schiff Award at Duke University, awarded to an outstanding Internal Medicine Resident, and The American College of Cardiology/Merck Award. He is a Fellow of The American College of Cardiology and was named one of the Best Doctors of America in 2003. His research interests include molecular mechanisms of viral heart disease and cardiomyopathies, as well as regulation of gene expression during ventricular hypertrophy and failure.

**Arnold Kriegstein, M.D., Ph.D.**

Director, Institute for Stem Cell and Tissue Biology, UCSF

Arnold Kriegstein, MD, PhD, is director of the UCSF Institute for Stem Cell and Tissue Biology, a position he has held since August 2004. He previously was the founding director of the Neural Stem Cell Center at Columbia University.

Dr. Kriegstein is trained as a neurologist -- a physician who treats patients with brain diseases and injuries -- and a neuroscientist -- a researcher who studies the brain. His research focuses on the way in which neural stem cells in the embryonic brain of rodents produce neurons (or nerve cells). He is interested in determining if these stem cells could someday be used to treat diseases in which neurons have died or been damaged, as in Parkinson's disease, stroke, spinal cord injury, Huntington's disease and amyotrophic lateral sclerosis (ALS). As director of the Institute, Dr. Kriegstein oversees one of the largest and most comprehensive stem cell programs in the United States. The Institute encompasses some 60 labs carrying out studies aimed at gaining fundamental information about human development, with an eye toward illuminating and treating a broad range of diseases and disorders, from heart disease and diabetes to birth defects, osteoporosis and cancer. Studies are conducted in adult and embryonic stem cells, and related cells, of humans, mice, zebra fish and worms.

The framework of the Institute is designed to allow basic researchers to drive their explorations toward investigations with their clinical-research colleagues at UCSF Medical Center, which has the medical and intellectual infrastructure to translate discoveries into therapeutic strategies. Born in Germany, Kriegstein received his undergraduate degree from Yale University and his MD and PhD degrees from New York University in 1977 where his thesis advisor was Eric Kandel. He has held academic appointments at New York University, Harvard University, Stanford University, Yale University, and Columbia University.

**Michael Marletta, Ph.D.**

Chair, Department of Chemistry, UC Berkeley

Dr. Michael A. Marletta is Professor of Chemistry and Chair, Department of Chemistry as well as Professor of Biochemistry and Molecular Biology at UC Berkeley. He is also an Aldo DeBenedictis Distinguished Professor and Joel Hildebrand Distinguished Professor at UC Berkeley, and holds a joint appointment as Professor of Cellular and Molecular Pharmacology at UCSF and as Faculty Scientist at the Lawrence Berkeley National Laboratory. He obtained his undergraduate degree in Biology and Chemistry from State University of New York, College at Fredonia, and his Ph.D. from the University of California, San Francisco.

Dr. Marletta was an NIH Postdoctoral Fellow at M.I.T., where he was also Assistant/Associate Professor. Before moving to UC Berkeley he was at the University of Michigan, where he first was Associate Professor and then Professor. Dr. Marletta has received several awards and distinctions, including the George H. Hitchings Award for Innovative Methods in Drug Discovery & Design; the Faculty Recognition Award, University of Michigan; the Outstanding Achievement Award, State University of New York College; the Distinguished Faculty Lectureship Award in Biomedical Research at the University of Michigan Medical School; The State of Michigan Scientist of the Year award; and the Distinguished Faculty Achievement Award, University of Michigan. He is an elected member of the Institute of Medicine and the National Academy of Sciences.

**Jagat Narula, M.D., D.M., Ph.D., F.A.C.C., F.A.H.A.**

Associate Dean, Chief of Cardiology, UC Irvine

Dr. Narula is the Professor of Medicine, Chief, Division of Cardiology and the Associate Dean for Research at the University of California, Irvine. He completed his cardiology training from All India Institute of Medical Sciences, Delhi, India, and relocated to Massachusetts General Hospital and Harvard Medical School in 1989. After completing his cardiology, heart failure & transplantation and nuclear cardiology fellowships, he joined the faculty at Mass General. In 1997, he moved to Philadelphia Hahnemann University School of Medicine. At Hahnemann, he was Thomas J. Vischer Professor of Medicine, Chief of Division of Cardiology, Vice-Chairman of Medicine, Director of the Heart Failure and Transplantation Center and Director of the Center for Molecular Cardiology until 2003 when he moved to UC.

Dr. Narula is predominantly involved in developing targeted imaging techniques for the detection of cardiac remodeling in heart failure and atherosclerosis in coronary disease. He is considered to be authority in the fields of programmed cell death and imaging of plaques that are likely to result in acute coronary syndromes. His research is funded, in part, by several NIH grants. Dr. Narula has authored more than 200 research publications and edited 20 books or journal supplements. He has been awarded as 'best young investigator' on several occasions, by the Cardiovascular Council and the American Society of Nuclear Cardiology. He serves on various American Heart Association and American Society of Nuclear Cardiology committees and is an associate editor of the Journal of American College of Cardiology and Editor of the Heart Failure Clinics of North America.

**Deepak Srivastava, M.D.**

Director, Gladstone Institute of Cardiovascular Disease

Dr. Srivastava is Director of the Gladstone Institute of Cardiovascular Disease and the Wilma and Adeline Distinguished Professor of Pediatrics at the University of California San Francisco (UCSF). Before joining Gladstone and UCSF in 2005, Dr. Srivastava was a professor in the Departments of Pediatrics and Molecular Biology at the University of Texas Southwestern (UTSW) Medical Center, where he also held the Joel B. Steinberg Chair and the Pogue Distinguished Chair, and was an attending physician at Childrens Medical Center of Dallas. He received a BA in biochemistry from Rice University and MD from the University of Texas Medical Branch. Dr. Srivastava completed his residency in the Department of Pediatrics at UCSF, and a fellowship in pediatric cardiology at the Children's Hospital of Harvard Medical School. His postdoctoral fellowship was at the M.D. Anderson Cancer Center as a fellow of the Pediatric Scientist Development Program before joining the UTSW faculty in 1996. Dr. Srivastava's laboratory investigates the causes of heart disease and uses knowledge of cardiac developmental pathways to devise novel therapeutic approaches for human cardiac disorders. He focuses on transcriptional and post-transcriptional steps, including those involving microRNAs, during these steps. They have also used human genetics to identify several novel causes of human congenital heart disease. Dr. Srivastava has received numerous honors and awards, including the Richard D. Rowe award from the Society for Pediatric Research, and has organized several international conferences. He has served on NIH and AHA Study Sections, and is currently serving on a Scientific Advisory Board for the March of Dimes and on the National Heart, Lung and Blood Institute's Strategic Planning Executive Committee. Dr. Srivastava's laboratory has trained more than 25 postdoctoral fellows and graduate students and he is committed to the training and development of physician-scientists.